Arcutis Biotherapeutics, Inc.
ARQT
$14.12
-$1.24-8.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 250.33% | 335.28% | 470.62% | 494.53% | 559.09% |
| Total Other Revenue | -93.10% | -93.15% | -1.38% | -7.96% | 13,709.52% |
| Total Revenue | 99.50% | 100.03% | 229.74% | 182.84% | 1,032.90% |
| Cost of Revenue | 183.11% | 231.13% | 283.56% | 348.51% | 338.74% |
| Gross Profit | 92.54% | 90.14% | 224.82% | 171.18% | 1,204.73% |
| SG&A Expenses | 19.29% | 21.10% | 23.90% | 27.07% | 29.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.02% | 10.33% | 8.06% | 7.82% | -4.89% |
| Operating Income | 52.25% | 38.25% | 46.75% | 26.74% | 43.15% |
| Income Before Tax | 52.75% | 39.68% | 46.20% | 26.30% | 40.94% |
| Income Tax Expenses | -72.00% | -82.15% | -78.77% | -88.46% | -- |
| Earnings from Continuing Operations | 53.07% | 40.34% | 46.58% | 27.01% | 39.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.07% | 40.34% | 46.58% | 27.01% | 39.92% |
| EBIT | 52.25% | 38.25% | 46.75% | 26.74% | 43.15% |
| EBITDA | 54.99% | 40.36% | 47.35% | 27.19% | 43.26% |
| EPS Basic | 65.90% | 64.22% | 70.23% | 59.00% | 60.54% |
| Normalized Basic EPS | 65.42% | 63.73% | 69.99% | 58.60% | 61.48% |
| EPS Diluted | 65.90% | 64.22% | 70.23% | 59.00% | 60.54% |
| Normalized Diluted EPS | 65.42% | 63.73% | 69.99% | 58.60% | 61.48% |
| Average Basic Shares Outstanding | 29.17% | 52.62% | 74.70% | 84.03% | 61.58% |
| Average Diluted Shares Outstanding | 29.17% | 52.62% | 74.70% | 84.03% | 61.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |